TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Discontinuation of amifostine treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Delay of radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: regional recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Physical function impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comorbidity burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for overall fit of FC2 compared to PFC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for lubrication of FC2 compared to PFC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for color of FC2 compared to PFC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IMA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean LH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: peak LH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incremental LH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: pulsatile LH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Regular skin checks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Co-morbid chronic medical conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic INR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: daily albuterol use reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthma symptoms reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noninferiority of single dose vs 2-dose regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearing of telangiectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swelling duration
Endpoint domain: Adverse events/effects
Primary endpoint: Erythema duration
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of esophageal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Light physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posterior muscle volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical parameters related to pain and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge and self-efficacy scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incisional surgical site infections (SSIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Organ/space surgical site infections (SSIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Remote infections (RIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Ongoing pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of OHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in specific conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in % predicted residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: H. pylori infection cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Development of post-transplant diabetes mellitus (PTDM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence rate of DENV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: size of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain associated with ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-adherence to asthma medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: daily incidence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Nausea frequency at 12 h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea scores at 3 h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery timing after tocolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Direct sedation costs for ERCP and bronchoscopy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Carotid-femoral pulse wave velocity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apnea events per tracing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bradycardia events per tracing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvements in overall quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative serum alanine aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Emergency department visits and hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Annual direct health care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in serologic hepatic tests (AST and ALT levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection or complication development
Endpoint domain: Adverse events/effects
Primary endpoint: Therapeutic results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain of infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax test/reference ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BCVA gain from baseline to week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of eyes gaining ≥15 letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of eyes losing ≥5 letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication rates of H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event rate of primary outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presentation for glaucoma examination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevention of acute CINV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of malalignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subsequent procedures per fracture
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Infections at surgical interfaces
Endpoint domain: Adverse events/effects
Primary endpoint: Hematological parameters (hemoglobin, hematocrit, platelet count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in disease phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in mitochondrial proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ciclosporin apparent oral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of MDMA in oral fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration levels of MDMA and MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Window of detection for MDMA and MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in lesion volume from acute to subacute scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25-hydroxyvitamin D (25(OH)D) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative GIQLI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Paw(peak) and Paw(plat) pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma leptin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cumulative net influence of knowledge on action
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: normal ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in BDI scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in GHQ scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in suicidal attempts
Endpoint domain: Adverse events/effects
Primary endpoint: Angina alleviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial ischemia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic blood pressure after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Yearly incidence of severe hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum triglycerides concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: diagnostic test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved performance on the Stroop Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of high on-treatment platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in plasma soluble CD40 ligand levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in plasma soluble P-selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DLNO at 90% VO(2)R
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: average coronary artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: new angiographic evidence of coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: death due to coronary artery disease or retransplantation
Endpoint domain: Mortality/survival
Primary endpoint: S:E ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall scleral surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematocrit level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MB level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CV death or HF at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: CD62P platelet expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fecal concentrations of elastase 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of secretin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive effects of the patient education programme
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of hypersensitivity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of anaphylaxis reactions
Endpoint domain: Adverse events/effects
Primary endpoint: return-to-work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Hbmass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unscheduled re‐presentation to medical care
Endpoint domain: Adverse events/effects
Primary endpoint: slowed down radiologic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LPP latency differentiation between negative and neutral pictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of moist desquamation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of maximum skin toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Time to development of grade 3 dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: women's felt acceptance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: relationship distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Renal ammoniagenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: personal growth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall success with lymph node sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arrhythmia occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of syncopal episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of presyncopal episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in patients' well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Radiographic improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in D(LCO) mean values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in SACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalence smoke-free rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of induction of anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: waking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: condition of the child after regaining consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: accidental decannulation
Endpoint domain: Adverse events/effects
Primary endpoint: Severe bleeding complications
Endpoint domain: Adverse events/effects
Primary endpoint: health service only costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: maternal sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: infant cooperativeness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: bioequivalence of risperidone formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean itch visual analogue score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean night itch severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fisk Fatigue Severity Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Attainment of euthyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction of free serum thyroxine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction of serum T4 values into hypothyroid range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean percentage decrease in hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: overall stone clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of mitral regurgitation (IMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of nasal obstruction and itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle peak torques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain and disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reactivity to acetaminophen and/or nimesulide
Endpoint domain: Adverse events/effects
Primary endpoint: Executive functioning behavior ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word reading accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new/worsening arthritis/arthralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Health professionals' intentions to improve practice
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: cold-related asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum coronary artery z score normalized to body surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean postcurriculum test scores of sexually transmitted disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: claudication distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean flow values in cutaneous microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Effectiveness of doxycycline for primary pterygia treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of local pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FEV1 changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PEF changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient preference for PVI over PIO
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Convenience of administration of PVI
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Ongoing pregnancy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of children hospitalised
Endpoint domain: Mortality/survival
Primary endpoint: Inhibition of allergen-induced symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increased vascular permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: rectus femoris activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: peak flexion of the trunk, knee, hip, and ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk extension during sit-to-stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mandibular opening range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral movement range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical pain occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in household inventory of fruits and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in coronary calcium score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in total serum cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes